Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
Top Page
Daito Pharmaceutical Co., Ltd.
(4577)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥1,538.00
▲(13.42% Upside)
Action:ReiteratedDate:10/16/25
Daito Pharmaceutical Co., Ltd. receives an overall score of 63, primarily influenced by its mixed financial performance and bearish technical indicators. While the company shows revenue growth, declining profit margins and increasing leverage are concerns. The stock's valuation is reasonable with an attractive dividend yield, but technical indicators suggest a lack of strong momentum. The absence of earnings call and corporate events data limits further insights.
Positive Factors
Contract manufacturing & API platform
A core business in contract manufacturing and API production creates durable, client-driven revenue streams and high switching costs. Long-term supply relationships with pharma customers support steady utilization, allow capacity leverage, and provide resilience versus single-product commercialization cycles.
Negative Factors
Declining profit margins
Material margin erosion over multiple years suggests persistent cost inflation or pricing pressure in products and services. Lower gross and net margins reduce internal cash available for capex, R&D, and dividends, weakening long-term competitiveness and return on equity if not reversed.
Read all positive and negative factors
Positive Factors
Negative Factors
Contract manufacturing & API platform
A core business in contract manufacturing and API production creates durable, client-driven revenue streams and high switching costs. Long-term supply relationships with pharma customers support steady utilization, allow capacity leverage, and provide resilience versus single-product commercialization cycles.
Read all positive factors
Daito Pharmaceutical Co., Ltd. (4577) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥43.09B
Dividend Yield2.75%
Average Volume (3M)63.87K
Price to Earnings (P/E)18.3
Beta (1Y)0.27
Revenue Growth7.56%
EPS Growth-48.91%
CountryJP
Employees1,070
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)35.21
Shares Outstanding30,096,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.58
Price to Sales (P/S)0.59
P/FCF Ratio-31.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Daito Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in var...
How the Company Makes Money
null...
Daito Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.98B | 50.64B | 46.90B | 45.10B | 43.46B | 48.71B |
| Gross Profit | 8.95B | 8.47B | 9.67B | 10.15B | 11.31B | 10.66B |
| EBITDA | 7.10B | 6.95B | 7.55B | 9.08B | 9.88B | 9.07B |
| Net Income | 1.99B | 1.91B | 3.29B | 3.60B | 4.67B | 4.25B |
Balance Sheet | ||||||
| Total Assets | 78.84B | 78.00B | 77.71B | 70.55B | 64.94B | 57.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.15B | 2.21B | 2.73B | 3.61B | 4.38B | 3.37B |
| Total Debt | 11.94B | 11.88B | 8.72B | 4.89B | 3.44B | 3.38B |
| Total Liabilities | 26.62B | 25.93B | 25.44B | 19.58B | 17.26B | 15.82B |
| Stockholders Equity | 52.17B | 52.00B | 52.07B | 50.67B | 47.31B | 41.62B |
Cash Flow | ||||||
| Free Cash Flow | -1.52B | -957.00M | -1.04B | -1.35B | -257.00M | -1.14B |
| Operating Cash Flow | 920.00M | 5.90B | 5.18B | 4.16B | 4.37B | 5.18B |
| Investing Cash Flow | -2.64B | -7.37B | -5.93B | -5.57B | -4.33B | -6.32B |
| Financing Cash Flow | 1.98B | 1.00B | -183.00M | 616.00M | 921.00M | 1.42B |
Daito Pharmaceutical Co., Ltd. Technical Analysis
Positive
1356.00
Price Trends
1424.00
Positive
1369.67
Positive
1263.66
Positive
Market Momentum
1.83
Positive
49.14
Neutral
24.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4577, the sentiment is Positive. The current price of 1356 is below the 20-day moving average (MA) of 1459.95, below the 50-day MA of 1424.00, and above the 200-day MA of 1263.66, indicating a neutral trend. The MACD of 1.83 indicates Positive momentum. The RSI at 49.14 is Neutral, neither overbought nor oversold. The STOCH value of 24.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4577.
Daito Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥73.77B | 8.62 | ― | 2.52% | 5.44% | -20.33% | |
73 Outperform | ¥119.10B | 12.60 | 4.81% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥89.22B | 8.41 | ― | 3.36% | 11.65% | 93.46% | |
68 Neutral | ¥63.78B | 35.63 | 5.01% | 2.39% | 12.01% | -51.38% | |
64 Neutral | ¥6.23B | 11.64 | ― | 3.21% | 4.25% | ― | |
63 Neutral | ¥43.09B | 18.30 | ― | 2.75% | 7.56% | -48.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4577
Daito Pharmaceutical Co., Ltd.
1,432.00
388.77
37.27%
JP:4554
Fuji Pharma Co., Ltd.
2,486.00
1,212.84
95.26%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,500.00
539.18
18.21%
JP:4539
Nippon Chemiphar Co., Ltd.
1,725.00
317.98
22.60%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,695.00
316.72
22.98%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,772.00
550.49
24.78%
Daito Pharmaceutical Co., Ltd. Corporate Events
Daito Pharmaceutical Advances Share Buyback, Repurchases 208,800 Shares in March
Apr 1, 2026
Daito Pharmaceutical Co., Ltd. has repurchased 208,800 shares of its common stock on the Tokyo Stock Exchange between March 1 and March 31, 2026, at a total cost of 305,442,800 yen. The transaction was executed under the authority of its Articles ...
Daito Pharmaceutical Advances Share Buyback Program on Tokyo Stock Exchange
Mar 2, 2026
Daito Pharmaceutical Co., Ltd. has repurchased 77,200 shares of its common stock on the Tokyo Stock Exchange between February 1 and February 28, 2026, for a total of 103,725,900 yen. This buyback is conducted under the authority of its Articles of...
Daito Pharmaceutical Continues Share Buybacks Under Ongoing Capital Management Program
Feb 2, 2026
Daito Pharmaceutical has repurchased 225,600 shares of its common stock for approximately 303 million yen via market purchases on the Tokyo Stock Exchange during January 2026, under the authority granted by its Articles of Incorporation and Japan&...
Daito Pharmaceutical Corrects Errors in FY2026 Second-Half Financial Presentation Materials
Jan 16, 2026
Daito Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange, focuses on developing and providing pharmaceutical and healthcare products. The company announced that it has identified e...
Daito Pharmaceutical Lifts Interim Profit and Confirms Outlook as Earnings Strengthen
Jan 14, 2026
Daito Pharmaceutical reported consolidated net sales of ¥25.14 billion for the six months ended November 30, 2025, up 2.3% year on year, with operating profit rising 10.6% to ¥1.63 billion and profit attributable to owners of parent jump...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.